# Clinical trial results:
# A Phase IIb, randomized, partially blind, active controlled, dose-range finding study of GSK3640254 compared to a reference arm of dolutegravir, each in combination with nucleoside reverse transcriptase inhibitors, in HIV-1 infected antiretroviral treatment-naive adults

## Summary

| | |
|---|---|
| EudraCT number | 2019-004435-23 |
| Trial protocol | PT FR DE IT |
| Global end of trial date | 29 May 2023 |

### Results information

| | |
|---|---|
| Result version number | v2 |
| This version publication date | 12 November 2023 |
| First version publication date | 21 September 2023 |
| Version creation reason | |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | 208379 |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04493216 |
| WHO universal trial number (UTN) | - |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | ViiV Healthcare |
| Sponsor organisation address | 980 GreatWest Road, Brentford,Middlesex, United Kingdom, TW8 9GS |
| Public contact | GSK Response Center, ViiV Healthcare, 1 8664357343, GSKClinicalSupportHD@gsk.com |
| Scientific contact | GSK Response Center, ViiV Healthcare, 1 8664357343, GSKClinicalSupportHD@gsk.com |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Interim |
| Date of interim/final analysis | 21 October 2022 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 05 September 2022 |
| Global end of trial reached? | Yes |
| Global end of trial date | 29 May 2023 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

To evaluate antiviral efficacy of GSK3640254 relative to DTG, each given in combination with 2 NRTIs, enabling the selection of an optimal dose for GSK3640254

Protection of trial subjects:

Not Applicable

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 18 November 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Argentina: 36 |
| Country: Number of subjects enrolled | Canada: 4 |
| Country: Number of subjects enrolled | France: 2 |
| Country: Number of subjects enrolled | Germany: 6 |
| Country: Number of subjects enrolled | Italy: 11 |
| Country: Number of subjects enrolled | Portugal: 8 |
| Country: Number of subjects enrolled | Russian Federation: 20 |
| Country: Number of subjects enrolled | South Africa: 16 |
| Country: Number of subjects enrolled | Spain: 41 |
| Country: Number of subjects enrolled | United States: 17 |
| Worldwide total number of subjects | 161 |
| EEA total number of subjects | 68 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 | 0 |

| | |
|---|---|
| months) | |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 160 |
| From 65 to 84 years | 1 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

The study is terminated based on company decision to stop compound development. The decision is not based on any safety or efficacy concerns. It reflects the company strategy for portfolio progression.

### Pre-assignment

Screening details:

The results presented are based on the data up to a maximum of Week 48 (Partially Blind Randomised Phase). Data analysis is still ongoing and additional results will be provided.

### Period 1

| | |
|---|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | GSK3640254 100 milligram(mg)+ Placebo+ ABC/3TC or FTC/TAF |

Arm description:

Participants with human immunodeficiency virus type 1 (HIV-1), orally received one 100 mg tablet per day of GSK3640254 and two tablets per day of matching placebo in a blinded setting. Open label dual nucleoside reverse transcriptase inhibitors (NRTIs) background therapies were given as one tablet per day of 600 mg abacavir (ABC) / 300 mg lamivudine (3TC) OR 200 mg emtricitabine (FTC) / 25 mg tenofovir alafenamide (TAF) orally.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | ABC/3TC or FTC/TAF |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Open label dual NRTI background therapies were given as one tablet per day of 600 mg abacavir (ABC) / 300 mg lamivudine (3TC) OR 200 mg emtricitabine (FTC) / 25 mg tenofovir alafenamide (TAF) orally.

| | |
|---|---|
| Investigational medicinal product name | 100 mg GSK3640254 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants with human immunodeficiency virus type 1 (HIV-1) infected antiretroviral treatment-naive adults orally received one 100 mg tablet per day of GSK3640254 and two tablets per day of matching placebo as blinded.

| | |
|---|---|
| **Arm title** | GSK3640254 150 mg + ABC/3TC or FTC/TAF |

Arm description:

Participants with HIV-1, orally received 150 mg (one 100 mg tablet + two 25 mg tablets per day) of GSK3640254 in a blinded setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | ABC/3TC or FTC/TAF |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Open label dual NRTI background therapies were given as one tablet per day of 600 mg abacavir (ABC) / 300 mg lamivudine (3TC) OR 200 mg emtricitabine (FTC) / 25 mg tenofovir alafenamide (TAF) orally.

| | |
|---|---|
| Investigational medicinal product name | 150 mg GSK3640254 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants with HIV-1 infected antiretroviral treatment-naive adults orally received 150 mg (one 100 mg tablet + two 25 mg tablets per day) of GSK3640254 as blinded.

| | |
|---|---|
| **Arm title** | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF |

Arm description:

Participants with HIV-1, orally received two 100 mg tablets (200 mg) per day of GSK3640254 and one tablet per day of matching placebo in a blinded setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | ABC/3TC or FTC/TAF |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Open label dual NRTI background therapies were given as one tablet per day of 600 mg abacavir (ABC) / 300 mg lamivudine (3TC) OR 200 mg emtricitabine (FTC) / 25 mg tenofovir alafenamide (TAF) orally.

| | |
|---|---|
| Investigational medicinal product name | 200 mg GSK3640254 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants with HIV-1 infected antiretroviral treatment-naive adults orally received two 100 mg tablets (200 mg) per day of GSK3640254 and one tablet per day of matching placebo as blinded.

| | |
|---|---|
| **Arm title** | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |

Arm description:

Participants with HIV-1, orally received one 50 mg tablet per day of DTG in an open label setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.

| | |
|---|---|
| Arm type | Active comparator |
| Investigational medicinal product name | ABC/3TC or FTC/TAF |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Open label dual NRTI background therapies were given as one tablet per day of 600 mg abacavir (ABC) / 300 mg lamivudine (3TC) OR 200 mg emtricitabine (FTC) / 25 mg tenofovir alafenamide (TAF) orally.

| | |
|---|---|
| Investigational medicinal product name | 50 mg DTG |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants with HIV-1 infected antiretroviral treatment-naive adults orally received one 50 mg tablet per day of DTG in an open label setting.

| **Number of subjects in period 1** | GSK3640254 100 milligram(mg)+ Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF |
|---|---|---|---|
| Started | 40 | 43 | 42 |
| Completed | 0 | 0 | 0 |
| Not completed | 40 | 43 | 42 |
| Consent withdrawn by subject | 1 | 1 | 1 |
| Physician decision | - | - | 1 |
| Adverse event, non-fatal | 1 | 4 | 5 |
| Protocol Deviation | 1 | 2 | - |
| Ongoing | 18 | 18 | 16 |
| Site closed | 14 | 15 | 11 |
| Lost to follow-up | 1 | 1 | - |
| Subject Reached Protocol-Defined Stopping Criteria | 4 | 2 | 8 |

| **Number of subjects in period 1** | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|
| Started | 36 |
| Completed | 0 |
| Not completed | 36 |
| Consent withdrawn by subject | 2 |
| Physician decision | - |
| Adverse event, non-fatal | 2 |
| Protocol Deviation | 2 |
| Ongoing | 16 |
| Site closed | 11 |
| Lost to follow-up | 1 |
| Subject Reached Protocol-Defined Stopping Criteria | 2 |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | GSK3640254 100 milligram(mg)+ Placebo+ ABC/3TC or FTC/TAF |
| Reporting group description: | |
| Participants with human immunodeficiency virus type 1 (HIV-1), orally received one 100 mg tablet per day of GSK3640254 and two tablets per day of matching placebo in a blinded setting. Open label dual nucleoside reverse transcriptase inhibitors (NRTIs) background therapies were given as one tablet per day of 600 mg abacavir (ABC) / 300 mg lamivudine (3TC) OR 200 mg emtricitabine (FTC) / 25 mg tenofovir alafenamide (TAF) orally. | |
| Reporting group title | GSK3640254 150 mg + ABC/3TC or FTC/TAF |
| Reporting group description: | |
| Participants with HIV-1, orally received 150 mg (one 100 mg tablet + two 25 mg tablets per day) of GSK3640254 in a blinded setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally. | |
| Reporting group title | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF |
| Reporting group description: | |
| Participants with HIV-1, orally received two 100 mg tablets (200 mg) per day of GSK3640254 and one tablet per day of matching placebo in a blinded setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally. | |
| Reporting group title | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
| Reporting group description: | |
| Participants with HIV-1, orally received one 50 mg tablet per day of DTG in an open label setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally. | |

| Reporting group values | GSK3640254 100 milligram(mg)+ Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF |
|---|---|---|---|
| Number of subjects | 40 | 43 | 42 |
| Age categorical<br>Units: Subjects | | | |
| 19-64 years | 40 | 42 | 42 |
| >=65 years | 0 | 1 | 0 |
| Sex: Female, Male<br>Units: Participants | | | |
| Female | 7 | 9 | 12 |
| Male | 33 | 34 | 30 |
| Race/Ethnicity, Customized<br>Units: Subjects | | | |
| AMERICAN INDIAN OR ALASKA NATIVE | 1 | 2 | 1 |
| ASIAN | 0 | 2 | 2 |
| BLACK OR AFRICAN AMERICAN | 6 | 8 | 6 |
| WHITE | 32 | 31 | 32 |
| MIXED RACE | 1 | 0 | 0 |
| MISSING | 0 | 0 | 1 |
| Age, Continuous<br>Units: YEARS | | | |
| arithmetic mean | 32.8 | 38.1 | 33.7 |
| standard deviation | ± 6.20 | ± 12.54 | ± 10.59 |

| **Reporting group values** | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF | Total | |
|---|---|---|---|
| Number of subjects | 36 | 161 | |
| Age categorical<br>Units: Subjects | | | |
| 19-64 years | 36 | 160 | |
| >=65 years | 0 | 1 | |
| Sex: Female, Male<br>Units: Participants | | | |
| Female | 10 | 38 | |
| Male | 26 | 123 | |
| Race/Ethnicity, Customized<br>Units: Subjects | | | |
| AMERICAN INDIAN OR ALASKA NATIVE | 0 | 4 | |
| ASIAN | 1 | 5 | |
| BLACK OR AFRICAN AMERICAN | 6 | 26 | |
| WHITE | 29 | 124 | |
| MIXED RACE | 0 | 1 | |
| MISSING | 0 | 1 | |
| Age, Continuous<br>Units: YEARS | | | |
| arithmetic mean | 35.3 | | |
| standard deviation | ± 9.85 | - | |

## End points

### End points reporting groups

| Reporting group title | GSK3640254 100 milligram(mg)+ Placebo+ ABC/3TC or FTC/TAF |
|---|---|

Reporting group description:

Participants with human immunodeficiency virus type 1 (HIV-1), orally received one 100 mg tablet per day of GSK3640254 and two tablets per day of matching placebo in a blinded setting. Open label dual nucleoside reverse transcriptase inhibitors (NRTIs) background therapies were given as one tablet per day of 600 mg abacavir (ABC) / 300 mg lamivudine (3TC) OR 200 mg emtricitabine (FTC) / 25 mg tenofovir alafenamide (TAF) orally.

| Reporting group title | GSK3640254 150 mg + ABC/3TC or FTC/TAF |
|---|---|

Reporting group description:

Participants with HIV-1, orally received 150 mg (one 100 mg tablet + two 25 mg tablets per day) of GSK3640254 in a blinded setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.

| Reporting group title | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF |
|---|---|

Reporting group description:

Participants with HIV-1, orally received two 100 mg tablets (200 mg) per day of GSK3640254 and one tablet per day of matching placebo in a blinded setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.

| Reporting group title | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|

Reporting group description:

Participants with HIV-1, orally received one 50 mg tablet per day of DTG in an open label setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.

### Primary: Percentage of participants with plasma HIV-1 ribonucleic acid (RNA) less than (<)50 copies per milliliter (c/mL) at Week 24

| End point title | Percentage of participants with plasma HIV-1 ribonucleic acid (RNA) less than (<)50 copies per milliliter (c/mL) at Week 24 |
|---|---|

End point description:

Percentage of participants with plasma HIV-1 RNA <50 c/mL at week 24 was assessed using the Food and Drug Administration (FDA) snapshot algorithm to demonstrate the antiviral activity of GSK3640254 given in combination with either ABC/3TC or FTC/TAF compared to the reference treatment of DTG given in combination with either ABC/3TC or FTC/TAF. Intent-to-Treat Exposed (ITT-E) population included all randomized participants who received at least one dose of study intervention.

| End point type | Primary |
|---|---|

End point timeframe:

At Week 24

| End point values | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 40 | 43 | 42 | 36 |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | 82.5 (68.1 to | 90.7 (78.4 to | 76.2 (61.5 to | 91.7 (78.2 to |

| | | | |
|---|---|---|---|
| 91.3) | 96.3) | 86.5) | 97.1) |

## Statistical analyses

| **Statistical analysis title** | Statistical Analysis 1 |
|---|---|
| Statistical analysis description: | |
| Differences in percentage of participant = Percentage of participant in GSK3640254 100 mg+ Placebo+ ABC/3TC or FTC/TAF - Percentage of participant in DTG+ABC/3TC or FTC/TAF | |
| Comparison groups | GSK3640254 100 milligram(mg)+ Placebo+ ABC/3TC or FTC/TAF v Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
| Number of subjects included in analysis | 76 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Differences in percentage of participant |
| Point estimate | -9.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -24 |
| upper limit | 5.7 |

| **Statistical analysis title** | Statistical Analysis 3 |
|---|---|
| Statistical analysis description: | |
| Differences in percentage of participant = Percentage of participant in GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF - Percentage of participant in DTG+ ABC/3TC or FTC/TAF | |
| Comparison groups | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF v Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
| Number of subjects included in analysis | 78 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Differences in percentage of participant |
| Point estimate | -15.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -31.2 |
| upper limit | 0.3 |

| **Statistical analysis title** | Statistical Analysis 2 |
|---|---|
| Statistical analysis description: | |
| Differences in percentage of participant = Percentage of participant in GSK3640254 150 mg+ ABC/3TC or FTC/TAF - Percentage of participant in DTG+ ABC/3TC or FTC/TAF | |
| Comparison groups | GSK3640254 150 mg + ABC/3TC or FTC/TAF v Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |

| | |
|---|---|
| Number of subjects included in analysis | 79 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Differences in percentage of participant |
| Point estimate | -1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -13.5 |
| upper limit | 11.6 |

## Secondary: Percentage of participants with plasma HIV-1 RNA <50 c/mL at Week 48

| | |
|---|---|
| End point title | Percentage of participants with plasma HIV-1 RNA <50 c/mL at Week 48 |

End point description:

Percentage of participants with plasma HIV-1 RNA <50 c/mL at week 48 was assessed using the FDA snapshot algorithm to demonstrate the antiviral activity of GSK3640254 given in combination with either ABC/3TC or FTC/TAF compared to the reference treatment of DTG given in combination with either ABC/3TC or FTC/TAF. Intent-to-Treat Exposed (ITT-E) population.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

At Week 48

| **End point values** | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 40 | 43 | 42 | 36 |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | 85.0 (70.9 to 92.9) | 83.7 (70.0 to 91.9) | 76.2 (61.5 to 86.5) | 77.8 (61.9 to 88.3) |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Absolute values of HIV-1 RNA at Weeks 24 and 48

| | |
|---|---|
| End point title | Absolute values of HIV-1 RNA at Weeks 24 and 48 |

End point description:

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA have been presented. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Exposed (ITT-E) population.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

| End point values | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 40 | 43 | 42 | 36 |
| Units: Log 10 copies per milliliter | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (Day 1) | 4.351 (± 0.5712) | 4.353 (± 0.6705) | 4.165 (± 0.6505) | 4.247 (± 0.6765) |
| Week 24 | 1.619 (± 0.1260) | 1.607 (± 0.0663) | 1.610 (± 0.0679) | 1.592 (± 0.0126) |
| Week 48 | 1.602 (± 0.0536) | 1.605 (± 0.0647) | 1.594 (± 0.0233) | 1.590 (± 0.0000) |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in plasma HIV-1 RNA at Weeks 24 and 48

| End point title | Change from Baseline in plasma HIV-1 RNA at Weeks 24 and 48 |
|---|---|

End point description:

Plasma samples were collected for quantitative analysis of HIV-1 RNA. log10 values for plasma HIV-1 RNA have been presented. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value. Intent-to-Treat Exposed (ITT-E) population.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48 - ITT-E population

| End point values | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 40 | 43 | 42 | 36 |
| Units: Log 10 copies per milliliter | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (Day 1) | 4.351 (± 0.5712) | 4.353 (± 0.6705) | 4.165 (± 0.6505) | 4.247 (± 0.6765) |

| | | | | |
|---|---|---|---|---|
| Change from Baseline to Week 24 | -2.718 (± 0.5501) | -2.784 (± 0.6615) | -2.565 (± 0.6513) | -2.629 (± 0.6835) |
| Change from Baseline to Week 48 | -2.675 (± 0.5640) | -2.762 (± 0.6784) | -2.580 (± 0.6941) | -2.717 (± 0.6672) |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Absolute values of Cluster of differentiation 4 plus (CD4+) cell counts at Weeks 24 and 48

| End point title | Absolute values of Cluster of differentiation 4 plus (CD4+) cell counts at Weeks 24 and 48 |
|---|---|

End point description:

Blood samples were collected and CD4+ cell count was assessed using flow cytometry. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Exposed (ITT-E) population.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

| End point values | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 40 | 43 | 42 | 36 |
| Units: Cells per cubic millimeter | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (Day 1) | 480.3 (± 171.72) | 509.7 (± 207.13) | 478.7 (± 204.04) | 514.1 (± 240.88) |
| Week 24 | 717.5 (± 222.91) | 643.5 (± 202.27) | 689.8 (± 316.64) | 724.8 (± 403.99) |
| Week 48 | 749.9 (± 328.28) | 702.6 (± 258.65) | 747.3 (± 313.15) | 705.2 (± 221.18) |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in CD4+ cell counts at Weeks 24 and 48

| End point title | Change from Baseline in CD4+ cell counts at Weeks 24 and 48 |
|---|---|

End point description:

Blood samples were collected and CD4+ cell count was assessed using flow cytometry. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value. Intent-to-Treat Exposed (ITT-E) population.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

| **End point values** | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 40 | 43 | 42 | 36 |
| Units: Cells per cubic millimeter | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (Day 1) | 480.3 (± 171.72) | 509.7 (± 207.13) | 478.7 (± 204.04) | 514.1 (± 240.88) |
| Change from Baseline to Week 24 | 241.3 (± 191.26) | 129.3 (± 233.07) | 202.3 (± 271.98) | 198.5 (± 285.00) |
| Change from Baseline to Week 48 | 292.4 (± 264.16) | 189.2 (± 216.10) | 243.0 (± 233.24) | 190.6 (± 180.19) |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Number of participants with serious adverse events (SAEs) and Deaths through Weeks 24 and 48**

| End point title | Number of participants with serious adverse events (SAEs) and Deaths through Weeks 24 and 48 |
|---|---|

End point description:

An SAE is defined as any serious adverse event that, at any dose results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or any other situation according to medical or scientific judgment. Safety population included all randomized participants who were exposed to study intervention with the exception of any participants with documented evidence of not having consumed any amount of study intervention.

| End point type | Secondary |
|---|---|

End point timeframe:

Up to Weeks 24 and 48

| **End point values** | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 40 | 43 | 42 | 36 |
| Units: Participants | | | | |

| | | | | |
|---|---|---|---|---|
| Week 24, SAEs | 2 | 4 | 2 | 2 |
| Week 48, SAEs | 2 | 7 | 2 | 2 |
| Week 24, Deaths | 0 | 0 | 0 | 0 |
| Week 48, Deaths | 0 | 0 | 0 | 0 |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with adverse events (AEs) leading to treatment discontinuation through Weeks 24 and 48

| End point title | Number of participants with adverse events (AEs) leading to treatment discontinuation through Weeks 24 and 48 |
|---|---|

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants who discontinued study treatment due to AEs are presented. Safety population.

| End point type | Secondary |
|---|---|

End point timeframe:

Up to Weeks 24 and 48

| End point values | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 40 | 43 | 42 | 36 |
| Units: Participants | | | | |
| Week 24 | 2 | 3 | 4 | 2 |
| Week 48 | 2 | 4 | 5 | 2 |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with AE based on maximum severity grades at Weeks 24 and 48

| End point title | Number of participants with AE based on maximum severity grades at Weeks 24 and 48 |
|---|---|

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The severity of AEs was defined as per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.1 and was categorized into grades as following: Grade 1 - mild, Grade 2 - moderate, Grade 3 - severe, Grade 4 - Potentially life threatening and Grade 5 - Fatal. Higher grade indicates more severe condition. Number of participants with adverse events by

maximum grade have been presented. Safety population. The data presented here is not a cumulative data but number of participants experiencing the adverse event based on maximum grade at the indicated timepoints.

| End point type | Secondary |
|---|---|

End point timeframe:

At Weeks 24 and 48

| **End point values** | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 40 | 43 | 42 | 36 |
| Units: Participants | | | | |
| Weeks 24, Grade 1 | 14 | 18 | 16 | 15 |
| Weeks 48, Grade 1 | 12 | 14 | 17 | 15 |
| Weeks 24, Grade 2 | 16 | 16 | 18 | 10 |
| Weeks 48, Grade 2 | 20 | 17 | 17 | 10 |
| Weeks 24, Grade 3 | 4 | 3 | 2 | 3 |
| Weeks 48, Grade 3 | 4 | 5 | 3 | 3 |
| Weeks 24, Grade 4 | 1 | 1 | 1 | 0 |
| Weeks 48, Grade 4 | 1 | 2 | 1 | 0 |
| Weeks 24, Grade 5 | 0 | 0 | 0 | 0 |
| Weeks 48, Grade 5 | 0 | 0 | 0 | 0 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with AEs of special interest (AESI) (gastrointestinal (GI), nervous system, and psychiatric AEs) through Weeks 24 and 48

| End point title | Number of participants with AEs of special interest (AESI) (gastrointestinal (GI), nervous system, and psychiatric AEs) through Weeks 24 and 48 |
|---|---|

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with AESI in (gastrointestinal (GI), nervous system, and psychiatric AEs) are presented. Safety population.

| End point type | Secondary |
|---|---|

End point timeframe:

At Weeks 24 and 48

| End point values | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 40 | 43 | 42 | 36 |
| Units: Participants | | | | |
| Week 24, AESI (Gastrointestinal) | 13 | 18 | 12 | 11 |
| Week 48, AESI (Gastrointestinal) | 14 | 18 | 14 | 14 |
| Week 24, AESI (Nervous system) | 5 | 4 | 7 | 3 |
| Week 48, AESI (Nervous system) | 7 | 5 | 8 | 3 |
| Week 24, AESI (Psychiatric) | 1 | 3 | 2 | 2 |
| Week 48, AESI (Psychiatric) | 4 | 3 | 4 | 4 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with genotypic resistance

| End point title | Number of participants with genotypic resistance |
|---|---|

End point description:

Plasma samples were collected for resistance testing. Genotypic testing was conducted in participants meeting protocol-defined virologic failure (PDVF) criteria. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. PDVF population included participant with A. virologic non-response (Decrease from Baseline in plasma HIV-1 RNA of 1.0 log10 c/mL unless plasma HIV-1 RNA is <200 c/mL by Week 12; confirmed plasma HIV-1 RNA levels ≥200 c/mL at or after Week 24; plasma HIV-1 RNA ≥50 c/mL on repeat testing of Week 24 results and prior to Week 28) and B. virologic rebound (confirmed plasma HIV-1 RNA ≥200 c/mL after confirmed consecutive plasma HIV-1 RNA <50 c/mL).

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

| End point values | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 2 | 5 | 1 |
| Units: Participants | | | | |
| Baseline (Day 1) | 0 | 0 | 0 | 0 |
| Weeks 24 | 0 | 0 | 0 | 0 |
| Weeks 48 | 0 | 0 | 0 | 0 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with phenotypic resistance

| End point title | Number of participants with phenotypic resistance |
|---|---|

End point description:

Plasma samples were collected to for resistance testing. Phenotypic testing was conducted in participants meeting PDVF criteria. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Protocol-defined virologic failure (PDVF) population. Only those participants with data available at specified time points have been analyzed.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

| **End point values** | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 2 | 5 | 1 |
| Units: Participants | | | | |
| Baseline (Day 1) | 0 | 0 | 0 | 0 |
| Weeks 24 | 0 | 0 | 0 | 0 |
| Weeks 48 | 0 | 0 | 0 | 0 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Observed plasma concentration at the end of the dosing interval (Ctau) of GSK3640254 at steady state - Week 24 and 48

| End point title | Observed plasma concentration at the end of the dosing interval (Ctau) of GSK3640254 at steady state - Week 24 and 48[1] |
|---|---|

End point description:

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3640254. Observed plasma concentration at the end of the dosing interval was determined directly from the concentration-time data. Sparse PK population included all participants who received at least one dose of GSK3640254 and have evaluable drug concentrations reported, where samples are collected according to the sparse PK sampling scheme. Only those participants who received GSK3640254 have been analyzed. Only those participants with data available at specified time points have been analyzed.

| End point type | Secondary |
|---|---|

End point timeframe:

At Weeks 24 and 48

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per objective of this endpoint, only analysis of GSK3640254 was planned to be presented

| End point values | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 | 10 | 13 | |
| Units: Nanogram/ milliliter (ng/mL) | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Week 24 | 396.5117 (± 62.5) | 519.6041 (± 84.9) | 922.9638 (± 51.6) | |
| Week 48 | 310.9877 (± 135.4) | 568.0656 (± 13.4) | 812.4745 (± 49.1) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Observed plasma concentration at the end of the dosing interval (Ctau) of GSK3640254 at steady state - Week 2

| End point title | Observed plasma concentration at the end of the dosing interval (Ctau) of GSK3640254 at steady state - Week 2[2] |
|---|---|

End point description:

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3640254. Observed plasma concentration at the end of the dosing interval was determined directly from the concentration-time data. Intensive pharmacokinetic (PK) population included all participants who received at least one dose of GSK3640254 and have evaluable drug concentrations reported, where samples are collected according to the intensive PK sampling scheme. Only those participants who received GSK3640254 have been analyzed.

| End point type | Secondary |
|---|---|

End point timeframe:

Pre-dose, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 10, and 24 hours post-dose at Week 2

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per objective of this endpoint, only analysis of GSK3640254 was planned to be presented

| End point values | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 14 | 13 | 18 | |
| Units: Nanogram/ milliliter (ng/mL) | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Week 2 | 430.5361 (± 56.5) | 604.8387 (± 44.2) | 805.2209 (± 43.7) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Area under the plasma drug concentration-time curve from pre-dose to the end of the dosing interval (AUC [0-tau]) of GSK3640254 at steady state

| End point title | Area under the plasma drug concentration-time curve from pre-dose to the end of the dosing interval (AUC [0-tau]) of GSK3640254 at steady state[3] |
|---|---|

End point description:

Blood samples were collected at indicated time points for PK analysis of GSK3640254. Intensive pharmacokinetic (PK) population. Only those participants who received GSK3640254 have been analyzed.

| End point type | Secondary |
|---|---|

End point timeframe:

Pre-dose, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 10, and 24 hours post-dose at Week 2

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per objective of this endpoint, only analysis of GSK3640254 was planned to be presented

| **End point values** | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 14 | 13 | 18 | |
| Units: Hour*nanogram/ milliliter (h*ng/mL) | | | | |
| geometric mean (geometric coefficient of variation) | 14995.7576 (± 49.8) | 21212.2480 (± 44.5) | 30708.2546 (± 40.1) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Observed pre-dose plasma concentration (C0) of GSK3640254 at steady state

| End point title | Observed pre-dose plasma concentration (C0) of GSK3640254 at steady state[4] |
|---|---|

End point description:

Blood samples were collected at indicated time points for PK analysis of GSK3640254. Observed pre-dose plasma concentration was determined directly from the concentration-time data. Intensive pharmacokinetic (PK) population. Only those participants who received GSK3640254 have been analyzed.

| End point type | Secondary |
|---|---|

End point timeframe:

Pre-dose, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 10, and 24 hours post-dose at Week 2

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per objective of this endpoint, only analysis of GSK3640254 was planned to be presented

| End point values | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 15 | 13 | 18 | |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | 435.9 (± 54.6) | 603.2 (± 59.5) | 865.2 (± 43.4) | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum observed concentration (Cmax) of GSK3640254 at steady state

| End point title | Maximum observed concentration (Cmax) of GSK3640254 at steady state[5] |
|---|---|

End point description:

Blood samples were collected at indicated time points for PK analysis of GSK3640254. Intensive pharmacokinetic (PK) population. Only those participants who received GSK3640254 have been analyzed.

| End point type | Secondary |
|---|---|

End point timeframe:

Pre-dose, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 10, and 24 hours post-dose at Week 2

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per objective of this endpoint, only analysis of GSK3640254 was planned to be presented

| End point values | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 15 | 13 | 18 | |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | 929.8 (± 45.9) | 1337.3 (± 47.7) | 2094.5 (± 39.2) | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Steady state oral clearance (CLt/F) of GSK3640254

| End point title | Steady state oral clearance (CLt/F) of GSK3640254[6] |
|---|---|

End point description:

Blood samples were collected at indicated time points for PK analysis of GSK3640254. Intensive pharmacokinetic (PK) population. Only those participants who received GSK3640254 have been analyzed.

| End point type | Secondary |
|---|---|

End point timeframe:

Pre-dose, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 10, and 24 hours post-dose at Week 2

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per objective of this endpoint, only analysis of GSK3640254 was planned to be presented

| **End point values** | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 14 | 13 | 18 | |
| Units: Liter/ hour | | | | |
| geometric mean (geometric coefficient of variation) | 6.6686 (± 49.8) | 7.0714 (± 44.5) | 6.5129 (± 40.1) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Cmax (Tmax) of GSK3640254 at steady state

| End point title | Time to Cmax (Tmax) of GSK3640254 at steady state[7] |
|---|---|

End point description:

Blood samples were collected at indicated time points for PK analysis of GSK3640254. Tmax was determined directly from the concentration-time data. Intensive pharmacokinetic (PK) population. Only those participants who received GSK3640254 have been analyzed.

| End point type | Secondary |
|---|---|

End point timeframe:

Pre-dose, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 10, and 24 hours post-dose at Week 2

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per objective of this endpoint, only analysis of GSK3640254 was planned to be presented

| **End point values** | GSK3640254 100 milligram(mg) + Placebo+ ABC/3TC or FTC/TAF | GSK3640254 150 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 15 | 13 | 18 | |
| Units: Hour | | | | |
| median (full range (min-max)) | 3.0000 (1.900 to 9.017) | 3.4167 (1.000 to 9.000) | 3.4583 (1.917 to 5.000) | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected maximum up to 48 weeks

Adverse event reporting additional description:

Safety population included all randomized participants who were exposed to study intervention with the exception of any participants with documented evidence of not having consumed any amount of study intervention. Data analysis is still ongoing and additional results will be provided.

| | |
|---|---|
| Assessment type | Systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 25.0 |

### Reporting groups

| | |
|---|---|
| Reporting group title | GSK3640254 100 milligram(mg)+ Placebo+ ABC/3TC or FTC/TAF |

Reporting group description:

Participants with human immunodeficiency virus type 1 (HIV-1), orally received one 100 mg tablet per day of GSK3640254 and two tablets per day of matching placebo in a blinded setting. Open label dual nucleoside reverse transcriptase inhibitors (NRTIs) background therapies were given as one tablet per day of 600 mg abacavir (ABC) / 300 mg lamivudine (3TC) OR 200 mg emtricitabine (FTC) / 25 mg tenofovir alafenamide (TAF) orally.

| | |
|---|---|
| Reporting group title | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF |

Reporting group description:

Participants with HIV-1, orally received one 50 mg tablet per day of DTG in an open label setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.

| | |
|---|---|
| Reporting group title | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF |

Reporting group description:

Participants with HIV-1, orally received two 100 mg tablets (200 mg) per day of GSK3640254 and one tablet per day of matching placebo in a blinded setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.

| | |
|---|---|
| Reporting group title | GSK3640254 150 mg + ABC/3TC or FTC/TAF |

Reporting group description:

Participants with HIV-1, orally received 150 mg (one 100 mg tablet + two 25 mg tablets per day) of GSK3640254 in a blinded setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.

| Serious adverse events | GSK3640254 100 milligram(mg)+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 40 (5.00%) | 2 / 36 (5.56%) | 2 / 42 (4.76%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Anogenital warts | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 40 (0.00%) | 0 / 36 (0.00%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 0 / 36 (0.00%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Limb fracture | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 0 / 36 (0.00%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| Abortion spontaneous | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 0 / 36 (0.00%) | 1 / 42 (2.38%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 0 / 36 (0.00%) | 1 / 42 (2.38%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 1 / 36 (2.78%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 1 / 40 (2.50%) | 0 / 36 (0.00%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Pulmonary hypertension | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 40 (0.00%) | 0 / 36 (0.00%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 0 / 36 (0.00%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Dermatitis allergic | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 0 / 36 (0.00%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Suicidal ideation | | | |
| subjects affected / exposed | 1 / 40 (2.50%) | 0 / 36 (0.00%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Substance dependence | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 1 / 36 (2.78%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 0 / 36 (0.00%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Necrotising fasciitis | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 0 / 36 (0.00%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 1 / 36 (2.78%) | 0 / 42 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | GSK3640254 150 mg + ABC/3TC or FTC/TAF | | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 7 / 43 (16.28%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Anogenital warts | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Limb fracture | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pregnancy, puerperium and perinatal conditions | | | |
| Abortion spontaneous | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Colitis | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|---|---|---|
| Hepatobiliary disorders | | | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Pulmonary hypertension | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Dermatitis allergic | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Psychiatric disorders | | | |
| Suicidal ideation | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Substance dependence | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Necrotising fasciitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 2 %

| **Non-serious adverse events** | GSK3640254 100 milligram(mg)+ Placebo+ ABC/3TC or FTC/TAF | Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF | GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 37 / 40 (92.50%) | 27 / 36 (75.00%) | 38 / 42 (90.48%) |
| Investigations | | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 3 / 40 (7.50%) | 1 / 36 (2.78%) | 1 / 42 (2.38%) |
| occurrences (all) | 3 | 1 | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Anogenital warts | | | |
| subjects affected / exposed | 1 / 40 (2.50%) | 0 / 36 (0.00%) | 1 / 42 (2.38%) |
| occurrences (all) | 1 | 0 | 1 |
| Injury, poisoning and procedural complications | | | |
| Limb injury | | | |
| subjects affected / exposed | 1 / 40 (2.50%) | 1 / 36 (2.78%) | 2 / 42 (4.76%) |
| occurrences (all) | 1 | 1 | 2 |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 2 / 40 (5.00%) | 0 / 36 (0.00%) | 1 / 42 (2.38%) |
| occurrences (all) | 2 | 0 | 1 |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 2 / 40 (5.00%) | 1 / 36 (2.78%) | 2 / 42 (4.76%) |
| occurrences (all) | 2 | 1 | 3 |
| Headache | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 6 / 40 (15.00%) | 3 / 36 (8.33%) | 7 / 42 (16.67%) |
| occurrences (all) | 6 | 4 | 10 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 2 / 40 (5.00%) | 1 / 36 (2.78%) | 3 / 42 (7.14%) |
| occurrences (all) | 2 | 2 | 3 |
| Pyrexia | | | |
| subjects affected / exposed | 4 / 40 (10.00%) | 1 / 36 (2.78%) | 1 / 42 (2.38%) |
| occurrences (all) | 5 | 1 | 1 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 2 / 40 (5.00%) | 2 / 36 (5.56%) | 3 / 42 (7.14%) |
| occurrences (all) | 2 | 2 | 3 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 1 / 40 (2.50%) | 3 / 36 (8.33%) | 3 / 42 (7.14%) |
| occurrences (all) | 1 | 3 | 3 |
| Diarrhoea | | | |
| subjects affected / exposed | 5 / 40 (12.50%) | 9 / 36 (25.00%) | 6 / 42 (14.29%) |
| occurrences (all) | 5 | 10 | 7 |
| Vomiting | | | |
| subjects affected / exposed | 2 / 40 (5.00%) | 0 / 36 (0.00%) | 0 / 42 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 2 / 36 (5.56%) | 0 / 42 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Nausea | | | |
| subjects affected / exposed | 2 / 40 (5.00%) | 1 / 36 (2.78%) | 3 / 42 (7.14%) |
| occurrences (all) | 2 | 1 | 3 |
| Toothache | | | |
| subjects affected / exposed | 0 / 40 (0.00%) | 1 / 36 (2.78%) | 2 / 42 (4.76%) |
| occurrences (all) | 0 | 1 | 2 |
| Dyspepsia | | | |
| subjects affected / exposed | 1 / 40 (2.50%) | 1 / 36 (2.78%) | 2 / 42 (4.76%) |
| occurrences (all) | 1 | 1 | 3 |
| Food poisoning | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 40 (5.00%) | 1 / 36 (2.78%) | 1 / 42 (2.38%) |
| occurrences (all) | 2 | 1 | 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Rhinitis allergic | | | |
| subjects affected / exposed | 3 / 40 (7.50%) | 1 / 36 (2.78%) | 1 / 42 (2.38%) |
| occurrences (all) | 3 | 1 | 1 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 2 / 40 (5.00%) | 3 / 36 (8.33%) | 2 / 42 (4.76%) |
| occurrences (all) | 2 | 4 | 2 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 1 / 40 (2.50%) | 3 / 36 (8.33%) | 1 / 42 (2.38%) |
| occurrences (all) | 1 | 3 | 1 |
| Infections and infestations | | | |
| Gonorrhoea | | | |
| subjects affected / exposed | 2 / 40 (5.00%) | 0 / 36 (0.00%) | 2 / 42 (4.76%) |
| occurrences (all) | 2 | 0 | 2 |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 40 (2.50%) | 0 / 36 (0.00%) | 2 / 42 (4.76%) |
| occurrences (all) | 1 | 0 | 2 |
| Chlamydial infection | | | |
| subjects affected / exposed | 2 / 40 (5.00%) | 1 / 36 (2.78%) | 1 / 42 (2.38%) |
| occurrences (all) | 2 | 1 | 2 |
| COVID-19 | | | |
| subjects affected / exposed | 10 / 40 (25.00%) | 10 / 36 (27.78%) | 6 / 42 (14.29%) |
| occurrences (all) | 12 | 13 | 7 |
| Influenza | | | |
| subjects affected / exposed | 3 / 40 (7.50%) | 4 / 36 (11.11%) | 3 / 42 (7.14%) |
| occurrences (all) | 3 | 5 | 3 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 4 / 40 (10.00%) | 3 / 36 (8.33%) | 3 / 42 (7.14%) |
| occurrences (all) | 5 | 6 | 5 |
| Monkeypox | | | |
| subjects affected / exposed | 1 / 40 (2.50%) | 1 / 36 (2.78%) | 2 / 42 (4.76%) |
| occurrences (all) | 1 | 1 | 2 |

| | | | |
|---|---|---|---|
| Pharyngitis | | | |
| subjects affected / exposed | 4 / 40 (10.00%) | 3 / 36 (8.33%) | 1 / 42 (2.38%) |
| occurrences (all) | 4 | 3 | 1 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 3 / 40 (7.50%) | 0 / 36 (0.00%) | 1 / 42 (2.38%) |
| occurrences (all) | 3 | 0 | 1 |
| Syphilis | | | |
| subjects affected / exposed | 3 / 40 (7.50%) | 5 / 36 (13.89%) | 3 / 42 (7.14%) |
| occurrences (all) | 3 | 6 | 3 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 4 / 40 (10.00%) | 1 / 36 (2.78%) | 3 / 42 (7.14%) |
| occurrences (all) | 5 | 1 | 5 |
| Urethritis | | | |
| subjects affected / exposed | 1 / 40 (2.50%) | 2 / 36 (5.56%) | 0 / 42 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |

| **Non-serious adverse events** | GSK3640254 150 mg + ABC/3TC or FTC/TAF | | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 37 / 43 (86.05%) | | |
| Investigations | | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences (all) | 0 | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Anogenital warts | | | |
| subjects affected / exposed | 2 / 43 (4.65%) | | |
| occurrences (all) | 2 | | |
| Injury, poisoning and procedural complications | | | |
| Limb injury | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences (all) | 1 | | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 2 / 43 (4.65%) | | |
| occurrences (all) | 2 | | |
| Nervous system disorders | | | |

| | | | |
|---|---|---|---|
| Dizziness | | | |
| subjects affected / exposed | 3 / 43 (6.98%) | | |
| occurrences (all) | 3 | | |
| Headache | | | |
| subjects affected / exposed | 4 / 43 (9.30%) | | |
| occurrences (all) | 4 | | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pyrexia | | | |
| subjects affected / exposed | 4 / 43 (9.30%) | | |
| occurrences (all) | 4 | | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences (all) | 1 | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 3 / 43 (6.98%) | | |
| occurrences (all) | 3 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 7 / 43 (16.28%) | | |
| occurrences (all) | 8 | | |
| Vomiting | | | |
| subjects affected / exposed | 3 / 43 (6.98%) | | |
| occurrences (all) | 3 | | |
| Haemorrhoids | | | |
| subjects affected / exposed | 2 / 43 (4.65%) | | |
| occurrences (all) | 2 | | |
| Nausea | | | |
| subjects affected / exposed | 6 / 43 (13.95%) | | |
| occurrences (all) | 8 | | |
| Toothache | | | |
| subjects affected / exposed | 2 / 43 (4.65%) | | |
| occurrences (all) | 3 | | |
| Dyspepsia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences (all) | 1 | | |
| Food poisoning | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Rhinitis allergic | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences (all) | 1 | | |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 2 / 43 (4.65%) | | |
| occurrences (all) | 3 | | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences (all) | 1 | | |
| Infections and infestations | | | |
| Gonorrhoea | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 2 / 43 (4.65%) | | |
| occurrences (all) | 2 | | |
| Chlamydial infection | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences (all) | 0 | | |
| COVID-19 | | | |
| subjects affected / exposed | 12 / 43 (27.91%) | | |
| occurrences (all) | 12 | | |
| Influenza | | | |
| subjects affected / exposed | 4 / 43 (9.30%) | | |
| occurrences (all) | 4 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 3 / 43 (6.98%) | | |
| occurrences (all) | 4 | | |

| | | | |
|---|---|---|---|
| Monkeypox | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences (all) | 1 | | |
| Pharyngitis | | | |
| subjects affected / exposed | 4 / 43 (9.30%) | | |
| occurrences (all) | 5 | | |
| Respiratory tract infection | | | |
| subjects affected / exposed | 0 / 43 (0.00%) | | |
| occurrences (all) | 0 | | |
| Syphilis | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences (all) | 1 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 3 / 43 (6.98%) | | |
| occurrences (all) | 3 | | |
| Urethritis | | | |
| subjects affected / exposed | 1 / 43 (2.33%) | | |
| occurrences (all) | 1 | | |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 25 September 2020 | This is a global amendment and was created primarily to replace details of the internal Safety Review Committee to reflect the use instead of an Independent Data Monitoring Committee (IDMC). The decision to switch was based on feedback received from several health authorities and ethics committees, with advice and approval by VH guidance committee. This amendment also includes corrections, clarifications and minor administrative errors.<br>In addition, details from 2 prior country-specific amendments (Canada amendment CAN-1 and Portugal amendment POR-1) were incorporated into this global amendment. |
| 09 April 2021 | This is a global amendment. This amendment was created primarily to make non-substantial changes generally related to inclusion/exclusion criteria and the screening period, esophagogastroduodenoscopy (EGD) biopsy-based stopping criteria for individual participants and the study overall. The other changes exist for further detail, clarity, and current information. |
| 10 May 2021 | Study 208379 is undergoing this substantial amendment to reduce the sample size from approximately 210 participants to approximately 150 participants. This reduction of 60 participants will occur equally among the 3 experimental arms. There is no change to the Dolutegravir (DTG) reference arm. Thus, the number of participants will be as follows (each arm in combination with open-label Nucleoside Reverse Transcriptase Inhibitor [NRTI] backbone as originally described): |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported